title: Comparison of mesenchymal stromal cells from young healthy donors and patients with severe chronic coronary artery disease.
abstract: BACKGROUND
  It has been questioned whether bone marrow-derived mesenchymal stromal cells (MSCs) from patients with ischemic heart disease are suitable for use in regenerative stem cell therapy. We compared MSCs from patients with chronic coronary artery disease (CAD) and MSCs from young healthy donors with respect to phenotype, proliferation and endothelial differentiation capacity.
  
  
  METHODS
  MSCs from 16 young healthy donors and 15 elderly CAD patients were isolated, expanded by ex-vivo cultivation for two cell passages and characterized by flow cytometry, real time PCR and angiogenesis assay.
  
  
  RESULTS
  MSCs from healthy donors and CAD patients expressed the same surface markers and had similar proliferation capacity. In both groups VEGF-stimulation significantly increased the expression of the endothelial genes thrombospondin 1, Tie-2 and von Willebrand Factor and induced the capacity to form ring structures on extracellular matrix.
  
  
  CONCLUSIONS
  MSCs from young healthy donors and CAD patients proliferate equally well, express the same surface markers and increase in endothelial gene expression and ring structure formation capacity in the angiogenesis assay upon VEGF-stimulation. MSCs from CAD patients do not seem to be inferior to MSCs from young healthy donors thus indicating that autologous MSCs may be suitable for cell therapy in CAD patients.
authors.affiliation: Cardiological Stem Cell Laboratory, The Heart Centre, Rigshospitalet Copenhagen University Hospital and Faculty of Health Science, Copenhagen, Denmark.
authors.forename: Tina
authors.initials: T
authors.lastname: Friis
authors.forename: Mandana
authors.initials: M
authors.lastname: Haack-Sørensen
authors.forename: Susanne Kofoed
authors.initials: SK
authors.lastname: Hansen
authors.forename: Louise
authors.initials: L
authors.lastname: Hansen
authors.forename: Lene
authors.initials: L
authors.lastname: Bindslev
authors.forename: Jens
authors.initials: J
authors.lastname: Kastrup
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation; D003324:Coronary Artery Disease / Q000473:pathology* / Q000628:therapy; D042783:Endothelial Cells / Q000378:metabolism; D005260:Female; D005786:Gene Expression Regulation; D006649:Histocompatibility Antigens / Q000378:metabolism; D006801:Humans; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000378:metabolism* / Q000473:pathology; D008875:Middle Aged; D042787:Receptor, TIE-2 / Q000235:genetics / Q000378:metabolism; D017154:Stromal Cells / Q000378:metabolism / Q000473:pathology / Q000637:transplantation; D019700:Thrombospondin 1 / Q000235:genetics / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology; D055815:Young Adult; D014841:von Willebrand Factor / Q000235:genetics / Q000276:immunology / Q000378:metabolism
chemical_list: D015703:Antigens, CD; D006649:Histocompatibility Antigens; D019700:Thrombospondin 1; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C029417:Von Willebrand antigen; D014841:von Willebrand Factor; D042787:Receptor, TIE-2